[细胞毒性药物在器官和肿瘤中的浓度：静脉注射和瘤内注射后的比较（作者译）]
[Concentrations of cytostatic drugs in organs and tumors: comparison after intravenous and intratumoral injection (author's transl)].
作者信息
Wenzel M, Schneider M, Bier J, Benders P, Schachschneider G
出版信息
J Cancer Res Clin Oncol. 1979 Oct;95(2):147-57. doi: 10.1007/BF00401009.
Abstract
The cytostatic drugs Chlorambucil and Bleomycin were labeled with 131I and with 57Co, respectively: Ruthenocenealdehyde-(N-methyl-N-beta-chlorethyl)-hydrazone and Ruthenocene-3-phenyl-prop.1-en-3-one were labeled with the gamma emitter 103Ru. In tumor-bearing mice the elimination and organ distribution of these radioactive substances were tested after intravenous (i.v.) and intratumoral (i.t.) injection of the drugs. The organ load showed lower values after i.t. than after i.v. application, while the radioactivity concentrations in the tumor were considerably increased after i.t. injection. The integrals of the concentration-time curves showed 10--80 times higher concentrations in the tumor after i.t. compared to i.v. injection of the drugs.
摘要
细胞抑制药物苯丁酸氮芥和博来霉素分别用¹³¹I和⁵⁷Co进行标记：钌茂醛 -（N - 甲基 - N - β - 氯乙基） - 腙和钌茂 - 3 - 苯基 - 丙 - 1 - 烯 - 3 - 酮用γ发射体¹⁰³Ru进行标记。在荷瘤小鼠中，静脉内（i.v.）和瘤内（i.t.）注射药物后，对这些放射性物质的消除和器官分布进行了测试。与静脉内给药相比，瘤内给药后器官负荷值较低，而瘤内注射后肿瘤中的放射性浓度显著增加。浓度 - 时间曲线的积分显示，与静脉内注射药物相比，瘤内注射后肿瘤中的浓度高10 - 80倍。
相似文献
1
[Concentrations of cytostatic drugs in organs and tumors: comparison after intravenous and intratumoral injection (author's transl)].[细胞毒性药物在器官和肿瘤中的浓度：静脉注射和瘤内注射后的比较（作者译）]
J Cancer Res Clin Oncol. 1979 Oct;95(2):147-57. doi: 10.1007/BF00401009.
2
Pharmacokinetics and metabolism of a new antitumor semisynthetic ether phospholipid, 14C-labeled plasmanyl-(N-acyl)ethanolamine, in mice bearing sarcoma Mc11.一种新型抗肿瘤半合成醚磷脂，即14C标记的浆膜酰基-（N-酰基）乙醇胺，在患有肉瘤Mc11的小鼠体内的药代动力学和代谢情况。
J Cancer Res Clin Oncol. 1994;120(11):662-7. doi: 10.1007/BF01245378.
3
In vitro and in vivo investigations for the development of cytostatic methylhydrazones.用于开发细胞生长抑制剂甲基腙的体外和体内研究。
J Cancer Res Clin Oncol. 1985;110(2):110-4. doi: 10.1007/BF00402721.
4
Experimental investigations into the carcinogenic effect of antitumor and immunosuppressive agents.抗肿瘤和免疫抑制剂致癌作用的实验研究。
J Cancer Res Clin Oncol. 1989;115(4):309-28. doi: 10.1007/BF00400957.
5
The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.拓扑替康治疗小细胞肺癌的临床疗效和成本效果：系统评价和经济评估。
Health Technol Assess. 2010 Mar;14(19):1-204. doi: 10.3310/hta14190.
6
Comparison of selective intra-arterial to standard intravenous administration in percutaneous electrochemotherapy (pECT) for liver tumors.经皮电化学疗法（pECT）治疗肝肿瘤时选择性动脉内给药与标准静脉给药的比较。
Radiol Oncol. 2025 Feb 27;59(1):100-109. doi: 10.2478/raon-2025-0017. eCollection 2025 Mar 1.
7
Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells.血管破坏剂的效果对替拉扎明敏感性和γ射线照射的依赖性，取决于其给药时间和肿瘤大小，并参考其对肿瘤内静止细胞的影响。
J Cancer Res Clin Oncol. 2007 Jan;133(1):47-55. doi: 10.1007/s00432-006-0145-1. Epub 2006 Aug 22.
8
Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.使用¹³¹I标记的抗表皮生长因子受体靶向纳米颗粒进行放射性核素治疗可抑制由表皮生长因子受体（EGFR）过表达引起的癌细胞生长。
J Cancer Res Clin Oncol. 2016 Mar;142(3):619-32. doi: 10.1007/s00432-015-2067-2. Epub 2015 Nov 16.
9
Kinetics of 57Co-bleomycin in mice after intravenous, subcutaneous and intratumoral injection.57钴-博来霉素经静脉、皮下及瘤内注射后在小鼠体内的动力学
Cancer. 1979 Oct;44(4):1194-200. doi: 10.1002/1097-0142(197910)44:4<1194::aid-cncr2820440405>3.0.co;2-z.
10
Interventions for the management of malignant pleural effusions: a network meta-analysis.恶性胸腔积液管理的干预措施：一项网状荟萃分析。
Cochrane Database Syst Rev. 2016 May 8;2016(5):CD010529. doi: 10.1002/14651858.CD010529.pub2.
引用本文的文献
1
Intratumoural administration of cisplatin in slow-release devices. I. Tumour response and toxicity.顺铂在缓释装置中的瘤内给药。I. 肿瘤反应与毒性。
Cancer Chemother Pharmacol. 1990;27(2):135-40. doi: 10.1007/BF00689098.
2
Intratumoural administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoural distribution.顺铂缓释装置瘤内给药：II. 药代动力学和瘤内分布
Cancer Chemother Pharmacol. 1991;27(5):347-53. doi: 10.1007/BF00688856.
本文引用的文献
1
Synthesis of tritium-labeled chlorambucil and aniline mustard of high specific activity.高比活度氚标记苯丁酸氮芥及苯胺氮芥的合成。
J Med Chem. 1974 Feb;17(2):194-7. doi: 10.1021/jm00248a010.
2
3
[Tumor affinity of 103 Ru-ruthenocen-derivatives and 67gallium citrate].[103钌-钌茂衍生物与枸橼酸镓的肿瘤亲和力]
Strahlentherapie. 1978 Jul;154(7):506-7.
4
The fate of [103Ru]ruthenocene in mice and rats.[103Ru]钌茂在小鼠和大鼠体内的命运。
Xenobiotica. 1978 Feb;8(2):107-12. doi: 10.3109/00498257809060389.
5
Regression of established tumors and induction of tumor immunity by intratumor chemotherapy.瘤内化疗使已形成的肿瘤消退并诱导肿瘤免疫。
J Natl Cancer Inst. 1976 Apr;56(4):829-32. doi: 10.1093/jnci/56.4.829.
6
[Biochemistry of metallocenes, II. Organ-distribution and thymus affinity of cinnamoyl-[103Ru]ruthenocene (author's transl)].[二茂金属的生物化学，II. 肉桂酰-[103Ru]二茂钌的器官分布及胸腺亲和性（作者译）]
Z Naturforsch C Biosci. 1977 Jul-Aug;32(7-8):473-81.
7
57Co-bleomycin kinetics in normal and tumour-bearing mice after systemic and local administration.正常小鼠和荷瘤小鼠经全身及局部给药后57钴-博来霉素的动力学
J Maxillofac Surg. 1979 Feb;7(1):32-40. doi: 10.1016/s0301-0503(79)80008-9.
8
Cobalt chelate of bleomycin. I. Physicochemical properties and distribution in tumor bearing mice.博来霉素钴螯合物。I. 理化性质及在荷瘤小鼠体内的分布
Chem Pharm Bull (Tokyo). 1977 Jul;25(7):1725-31. doi: 10.1248/cpb.25.1725.
9
Comparison of radiolabeled bleomycins and gallium citrate in tumor-bearing mice.荷瘤小鼠体内放射性标记博来霉素与枸橼酸镓的比较。
J Nucl Med. 1977 Mar;18(3):276-81.
10
Attempt at local administration of anticancer agents in the form of fat emulsion.尝试以脂肪乳剂的形式进行抗癌药物的局部给药。
Cancer. 1976 Oct;38(4):1507-14. doi: 10.1002/1097-0142(197610)38:4<1507::aid-cncr2820380411>3.0.co;2-v.
Zotero 插件